Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB has initiated a rights issue of series A shares, aiming to raise approximately MSEK 136, with the subscription period running from July 3 to July 17, 2025. The rights issue, which is largely secured by subscription and guarantee undertakings, allows existing shareholders to purchase additional shares, although non-participating shareholders may experience dilution of up to 42.9% of their holdings.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB operates in the pharmaceutical industry, focusing on the development of novel treatments for neurological disorders. The company is primarily involved in creating therapies that address the needs of patients with Parkinson’s disease and other central nervous system conditions.
Average Trading Volume: 59,058
Current Market Cap: SEK340.4M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.